Credit Suisse’s Asterias Biotherapeutics Inc. Series A AST Stock Holding History

Credit Suisse’s Portfolio AST Stock Details AST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-11,049	Closed	-$16K	–	4306
2018 Q1	$16K	Buy	+11,049	New	+$23.1K	﹤0.01%	3929
2017 Q4	–	Sell	-17,613	Closed	-$60K	–	4401
2017 Q3	$60K	Buy	+17,613	New	+$59.3K	﹤0.01%	4135
2016 Q4	–	Sell	-14,692	Closed	-$62K	–	4380
2016 Q3	$62K	Sell	14,692 -6,734	-31%	-$21.8K	﹤0.01%	3995
2016 Q2	$51K	Buy	+21,426	New	+$77.5K	﹤0.01%	4149
2015 Q3	–	Sell	-22,906	Closed	-$106K	–	4762
2015 Q2	$106K	Sell	22,906 -23,980	-51%	-$230K	﹤0.01%	4378
2015 Q1	$316K	Buy	46,886 +18,700	+66%	+$92.6K	﹤0.01%	3835
2014 Q4	$91K	Buy	+28,186	New	+$113K	﹤0.01%	4452

Other funds holding AST

Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NFC

Northeast Financial Consultants Westport, Connecticut $2.45B AUM 15.14% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

ECM

Element Capital Management New York $1.05B AUM 5.05% 1-Year Est. Return

Paloma Partners Greenwich, Connecticut $510M AUM 286.05% 1-Year Est. Return

Credit Suisse's AST Position: Q2 2018 in Review

Credit Suisse sold out of Asterias Biotherapeutics Inc. Series A (AST) in Q2 2018, closing a stake of 11,049 shares — an estimated $16K sold.

Credit Suisse first reported a position in AST in Q4 2014 and held it in 7 quarters. The position peaked at $316K in Q1 2015. 62 funds tracked by Wall St. Rank hold AST as of Q2 2018.

Credit Suisse reported no remaining Asterias Biotherapeutics Inc. Series A position as of Q2 2018 after selling out during the quarter.
Credit Suisse sold 11,049 Asterias Biotherapeutics Inc. Series A shares in Q2 2018, an estimated $16K.
Credit Suisse first reported a position in Asterias Biotherapeutics Inc. Series A in Q4 2014 and held it in 7 quarters.
Credit Suisse's Asterias Biotherapeutics Inc. Series A position peaked at $316K in Q1 2015.
62 funds tracked by Wall St. Rank held Asterias Biotherapeutics Inc. Series A as of Q2 2018.

Based on Credit Suisse's 13F filing for Q2 2018, filed 14 Aug 2018.